Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Cardiology-CTVS
  • Cardiology & CTVS News
  • Minimally invasive...

Minimally invasive valve repair reduces heart failure hospitalizations in patients with severe tricuspid regurgitation: Study

Dr. Kamal Kant KohliWritten by Dr. Kamal Kant Kohli Published On 2025-04-15T20:45:08+05:30  |  Updated On 15 April 2025 8:45 PM IST
Minimally invasive valve repair reduces heart failure hospitalizations in patients with severe tricuspid regurgitation: Study
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received the best available medical therapy plus a minimally invasive procedure using a clip to repair the valve were 28% less likely to be hospitalized for recurrent heart failure than similar patients who were initially randomly assigned to medical therapy alone. The study was presented at the American College of Cardiology’s Annual Scientific Session (ACC.25).

“At two years, transcatheter edge-to-edge repair (TEER) for the treatment of symptomatic, severe tricuspid regurgitation appears to be safe, significantly reduced symptom severity and decreased the rate of recurrent hospitalization for heart failure compared with medical therapy alone,” said Saibal Kar, MD, program director for cardiovascular disease fellowship at Los Robles Health System in California, National Physician Leader, Interventional Cardiology, HCA Healthcare USA and first author of the study.

“This is the first and largest prospective randomized controlled trial to compare transcatheter device therapy plus medical therapy with medical therapy alone for severe tricuspid regurgitation, and these results represent the longest follow-up to date,” Kar said.

The tricuspid valve, one of four valves in the heart, controls blood flow from the right atrium (the heart’s upper-right chamber) to the right ventricle (the lower-right chamber). Tricuspid regurgitation occurs when the valve leaks, allowing blood to flow back into the right atrium. When this happens, the heart has to work harder to pump blood effectively. Patients with severe tricuspid regurgitation frequently have symptoms such as severe fatigue and shortness of breath, an enlarged liver, kidney failure and fluid accumulation in the abdomen, legs, ankles or feet.

Currently, the best available medical therapy for tricuspid regurgitation is diuretic medications that reduce fluid buildup in the body but often do not directly treat the mechanical leakage of blood through the tricuspid valve, Kar said.

The TRILUMINATE Pivotal trial was designed to determine whether patients at intermediate or greater risk for complications from tricuspid valve surgery would benefit from medical therapy plus TEER using a TriClip device, a minimally invasive procedure in which a catheter (a long flexible tube) is used to place one or more tiny clips on the tricuspid valve leaflets to prevent blood from leaking back into the right atrium.

In this randomized controlled trial, patients were randomly assigned to receive TEER and medical therapy or medical therapy alone. Patients deemed highly likely to achieve a reduction in tricuspid regurgitation to moderate or less were enrolled. The current study reports two-year follow-up results.

A total of 572 patients (mean age 78 years, 60% women) in five countries (United States, Canada, Germany, Italy and Spain) were enrolled in the randomized trial. All patients had severe tricuspid regurgitation; 55.1% had severe heart failure symptoms despite receiving the best available medical therapy; 50% had tricuspid regurgitation rated as “torrential” (the highest level of severity on a five-level scale); and 23.8% had been hospitalized for heart failure within the previous year.

All patients continued to take their medications for tricuspid regurgitation and heart failure while in the study. A central selection committee of heart specialists oversaw the patients’ medical treatment and confirmed that it was appropriate, Kar said. Half of the patients (the TEER group) were randomly assigned to have the TriClip device placed in the tricuspid valve. The other half did not undergo this procedure and served as a control group.

The study’s primary endpoint was a composite of death from any cause or tricuspid valve surgery, hospitalization for heart failure and quality of life improvement at one year. Two-year secondary endpoints were recurrent hospitalizations for heart failure and freedom from death due to any cause or the need for tricuspid valve surgery or another valve-repair procedure.

At two years, 77.6% of patients in the TEER group were alive and free from the need for tricuspid valve surgery or another valve-repair procedure, compared with 29.3% of control patients. This difference was driven by many of the control patients “crossing over” to receive TriClip treatment once eligible after one-year of follow up and if their symptoms remained severe, Karr said. At the two-year analysis, 60% of control patients had crossed over and been treated with the TriClip device,

The rate of recurrent hospitalizations for heart failure per patient each year was 0.19 for patients in the TEER group, compared with 0.26 in the control group. This difference was statistically significant and associated with a 28% reduction in the risk of recurrent hospitalization for heart failure at two years for patients who received the TriClip compared with controls, Kar said.

The number of patient deaths and the number of patients who needed tricuspid valve surgery during the two-year follow-up period was similar in both groups. No patients in the TEER group experienced blood clots or needed treatment with blood-thinning medications specifically due to the device, Kar said. At two years, tricuspid regurgitation severity was moderate or less for 84% of the patients in the TEER group, compared with 21% in the control group that remained on medical therapy alone.

The patients will be followed for a total of five years to evaluate the continued effectiveness, safety and durability of the TEER device, he said.

A limitation of the study is that it was unblinded, meaning both patients and their clinicians knew who had received TEER and who had not, Kar said. However, experts independent of the study sponsor assessed the hospitalizations, deaths and other adverse events that occurred in the study. In addition, the study findings are limited to patients with tricuspid regurgitation features deemed more amenable to a reduction in regurgitation to moderate or less.

Reference:

Minimally invasive valve repair reduces heart failure hospitalizations in patients with severe tricuspid regurgitation, American College of Cardiology, Meeting:American College of Cardiology's Annual Scientific Session.

American College of CardiologyCirculationheart failuretricuspid regurgitationcardiovascular disease
Source : Circulation
Dr. Kamal Kant Kohli
Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

Show Full Article
Next Story

Editorial

National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

Relevance of Pioglitazone in Indian T2DM Care Continuum

Relevance of Pioglitazone in Indian T2DM Care Continuum

Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

View All

Journal Club Today

Study Reveals Why Your Immune System Works Better in Daylight

Study Reveals Why Your Immune System Works Better in Daylight

View All

Health News Today

Health Bulletin 29/May/2025

Health Bulletin 29/May/2025

View All
© 2022 All Rights Reserved.
Powered By: Hocalwire
X
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok